OTX-TKI: Inside the SOL-1 Data - Poll - MDSpire

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

  • By

  • Dilsher S. Dhoot, MD

  • July 15, 2026

  • 3 min

Share

Original Source(s)

OTX-TKI: Inside the SOL-1 Data

  • by Dilsher S. Dhoot, MD

  • July 15, 2026

Related Content

Elevated GDF15 in ocular fluids of patients with proliferative diabetic retinopathy

PCG with biallelic CYP1B1 and CPAMD8 variants: a longitudinal case report

Can Oral Gildeuretinol Slow Advanced Macular Degeneration?

Although the trial missed its primary endpoint, exploratory analyses suggested slower lesion growth and better functional outcomes with gildeuretinol.